The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Subclassification of Serous Borderline Tumors of the Ovary into Benign Malignant Types: A Clinicopathologic Study of 65 Advanced Stage Cases
Abstract
Poor outcome in serous borderline tumors (SBT) of the ovary is limited to patients with advanced stage disease. This study was designed to determine whether there are histologic features among advanced-stage SBTs (International Federation of Gynecology and Obstetrics [FIGO] stages II and III) that predict behavior. The 65 cases in the study were divided into three groups: typical SBTs, with noninvasive implants (51 cases), SBTs with invasive implants (three cases), and a recently described tumor, designated micropapillary serous carcinoma (MPSC) (11 cases), a proliferative serous ovarian neoplasm that often lacks destructive infiltrative growth but appears to behave as a low-grade invasive carcinoma. When the tumor lacks infiltrative growth, as it did in the 11 cases in this series, it qualifies as a borderline tumor. After censoring nontumor deaths, the 5- and 10-year actuarial survival rates were 98% for SBTs with noninvasive implants, 33% for SBTs with invasive implants, and 81% at 5 years and 71% at 10 years for MPSCs. The mean follow-up was 100 months. Two (4%) of 51 patients with SBTs with noninvasive implants subsequently developed invasive carcinoma, and one (2%) died of carcinoma. In contrast, two (67%) of three women with SBTs accompanied by invasive implants developed invasive carcinoma, and both died of disease. Finally, of the 11 patients with MPSC, seven (64%), all of whom had invasive implants, developed recurrences of invasive carcinoma and/or died of tumor. MPSCs had significantly higher rates of mortality (p < 0.001) and recurrence as invasive carcinoma (p < .002) than SBTs with noninvasive implants. The recognition that SBTs can be divided into benign and malignant subtypes provides the basis for replacing the borderline category. The benign subgroup is composed of typical SBTs, including those with noninvasive implants for which the term atypical proliferative serous tumor is appropriate. In contrast, tumors displaying a micropapillary growth pattern (MPSC) and SBTs with invasive implants should be classified as carcinomas and treated accordingly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Kurman, R. J., Kaminski, P. F., & Norris, H. J. (1985) · Cancer · doi:10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x · Cited by 1,252
Self-citationBurks, R. T., Sherman, M. E., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00003 · Cited by 314
Self-citationStudies on Bilirubin in Amniotic Fluid: With Special Reference to Liver Function Tests
Ojala, A. (1971) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016347109157182 · Cited by 271
Serous Borderline Tumors of the Peritoneum
Bell, D. A., & Scully, R. E. (1990) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199003000-00004 · Cited by 168
The Behavior of Serous Tumors of Low Malignant Potential
Kurman, R. J., & Trimble, C. L. (1993) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199304000-00006 · Cited by 161
Self-citationBarnhill, D. R., Kurman, R. J., Brady, M. F., Omura, G. A., Yordan, E., Given, F. T., Kucera, P. R., & Roman, L. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2752 · Cited by 159
Self-citationSerous ovarian tumors of low malignant potential with peritoneal implants
Gershenson, D. M., & Silva, E. G. (1990) · Cancer · Cited by 138
The pathological assessment of ovarian neoplasms. II: The proliferating ‘epithelial’ tumours
Russell, P. J. (1979) · Pathology · doi:10.3109/00313027909061951 · Cited by 102
Cited by
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationColombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationMcCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
Kurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Self-citation
Metadata
- Authors
- Seidman, J. D., & Kurman, R. J.
- Venue
- The American Journal of Surgical Pathology
- Published
- 1996-11
- Volume
- 20
- Issue
- 11
- Pages
- 1331-1345
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2040247092
- Cited by
- 290
- References
- 13
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subclassification of Serous Borderline Tumors of the Ovary into Benign Malignant Types: A Clinicopathologic Study of 65 Advanced Stage Cases. https://app.cochat.ai/papers/10.1097/00000478-199611000-00004
- The paper
- Seidman, J. D., & Kurman, R. J. (1996). Subclassification of Serous Borderline Tumors of the Ovary into Benign Malignant Types: A Clinicopathologic Study of 65 Advanced Stage Cases. The American Journal of Surgical Pathology. https://doi.org/10.1097/00000478-199611000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.